Appendix Table 7.

Estimated 48-week risks, risk differences and risk ratios of COVID-19 outcomes by third antiretroviral drug in HIV-positive individuals,^* CoVIHd Collaboration, Spain, February-December 2020

	Documented SARS-CoV-2 infection				Hospitalization due to COVID-19				ICU admission due to COVID-19				COVID-19 death
	No. events	Risks (95%CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)	No. events	Risks (95%CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)	No. events	Risks (95% CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)	No. events	Risks (95% CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)
II	1,140	4.6 (4.3, 4.9)	0	1.00	214	0.8 (0.7, 1.0)	0	1.00	23	0.08 (0.05,0.12)	0	1.00	12	0.04 (0.02,0.07)	0	1.00
PI	231	5.0 (4.2, 5.7)	0.35 (−0.48,1.19)	1.08 (0.90, 1.27)	42	1.0 (0.6, 1.4)	0.12 (−0.28,0.56)	1.14 (0.70, 1.71)	4	0.08 (0.02,0.17)	−0.007 (−0.07,0.08)	0.92 (0.20, 2.22)	4	0.15 (0.03,0.36)	0.11 (−0.02,0.31)	3.69 (0.62,10.77)
NNRTI	533	5.2 (4.7, 5.7)	0.62 (0.03, 1.21)	1.13 (1.01, 1.28)	83	0.9 (0.7, 1.1)	0.04 (−0.20,0.29)	1.04 (0.77, 1.37)	10	0.16 (0.06,0.30)	0.08 (−0.02,0.22)	2.00 (0.74, 4.25)	12	0.19 (0.09,0.32)	0.15 (0.04, 0.28)	4.47 (1.68,11.73)

II: Integrase inhibitor, PI: protease inhibitor, NNRTI: non-nucleoside reverse-transcriptase inhibitor

^*Adjusted via inverse probability weighting for NRTI combination (TAF/FTC, TDF/FTC, ABC/3TC), age (in years, linear and quadratic terms), sex (male, female), transmission category (heterosexual, homo/bisexual, injecting drug use, other), country of origin (Spain, other), CD4 (<350, 350–500, >500 cells/mm3), and hypertension, diabetes, chronic renal disease, cardiovascular disease, and treatment with immunosuppressants or corticosteroids.